KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash & Equivalents: 2019-2024

Historic Cash & Equivalents for AbCellera Biologics (ABCL) over the last 6 years, with Dec 2024 value amounting to $625.6 million.

  • AbCellera Biologics' Cash & Equivalents fell 22.93% to $495.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $495.7 million, marking a year-over-year decrease of 22.93%. This contributed to the annual value of $625.6 million for FY2024, which is 17.75% down from last year.
  • AbCellera Biologics' Cash & Equivalents amounted to $625.6 million in FY2024, which was down 17.75% from $760.6 million recorded in FY2023.
  • AbCellera Biologics' 5-year Cash & Equivalents high stood at $886.5 million for FY2022, and its period low was $594.1 million during FY2020.
  • For the 3-year period, AbCellera Biologics' Cash & Equivalents averaged around $757.6 million, with its median value being $760.6 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 7,765.96% in 2020, then decreased by 17.75% in 2024.
  • Over the past 5 years, AbCellera Biologics' Cash & Equivalents (Yearly) stood at $594.1 million in 2020, then rose by 21.69% to $723.0 million in 2021, then climbed by 22.62% to $886.5 million in 2022, then fell by 14.20% to $760.6 million in 2023, then fell by 17.75% to $625.6 million in 2024.